#United States #New York #Levi & Korsinsky #Shareholder Rights #BioAge Labs

Crucial Information for BioAge Labs Shareholders

As a shareholder of BioAge Labs, Inc. (NASDAQ: BIOA), it's essential to be aware of your rights amid a significant class action lawsuit that could impact your investment. Levi & Korsinsky, LLP has reached out to investors regarding this legal action, and you may have the opportunity to recover losses resulting from alleged securities fraud.

What Happened?

The class action lawsuit targets BioAge Labs, focusing on claims that the company engaged in misleading practices regarding its financial wellbeing and product trials. The lawsuit encompasses all shareholders who purchased stock stemming from the company's initial public offering on or about September 26, 2024.

On December 6, 2024, BioAge disclosed that it would halt its STRIDES Phase 2 trial of azelaprag, its leading product, due to safety concerns, specifically elevated liver transaminase levels found in trial participants. This revelation came as a shock to many, especially considering the promising narrative BioAge conveyed during their IPO just months earlier about azelaprag's potential benefits for patients undergoing obesity therapy with incretin drugs.

The immediate aftermath of this announcement was drastic. BioAge's stock price plummeted from $20.09 on December 6, 2024, to a mere $4.65 by the following day. This decline underlined the severe impact of the company's unexpected decision and the lack of information provided to investors during the IPO.

Your Rights as an Investor

If you acquired shares of BioAge during the relevant time period and suffered financial losses, it’s crucial to act promptly. You have until March 10, 2025, to request that the court appoint you as a lead plaintiff in this case. While your ability to recover losses does not hinge on this role, expressing your interest in leading the case formalizes your position.

For those concerned about related expenses, it is worth noting that participating as a class member in this lawsuit involves no out-of-pocket costs or fees. Eligible shareholders may secure potential compensation without financial risk.

Why Choose Levi & Korsinsky?

Levi & Korsinsky stands out as a firm with an extensive track record of success in securities litigation, having secured hundreds of millions of dollars for aggrieved shareholders over the past two decades. The firm features a dedicated team of over 70 professionals ready to support investors navigating complex legal matters.

With its reputation affirmed by the ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky is a recognized leader in representing investors in high-stakes financial disputes.

Contact Information

If you believe you are affected by this lawsuit or wish to learn more about your rights, you can reach out directly to the firm:

• - Joseph E. Levi, Esq.

Email: [email protected]
Phone: (212) 363-7500

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

For more details, visit their site at Levi & Korsinsky.

Conclusion

As a shareholder of BioAge Labs, staying informed and proactive can significantly influence the outcome of this situation. Ensure you reach out to Levi & Korsinsky before the deadline to protect your investment rights and explore available options.